Open Access<p>Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan</p>
Author(s) -
Yasuhiro Kamioka,
Shota Kashiwagura,
Masafumi Seki
Publication year - 2020
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 27
ISSN - 1179-1438
DOI - 10.2147/cpaa.s268666
Subject(s) - oseltamivir , medical prescription , medicine , influenza season , zanamivir , virus , virology , winter season , covid-19 , veterinary medicine , pharmacology , influenza vaccine , infectious disease (medical specialty) , disease , climatology , geology
The use of baloxavir, a new anti-influenza agent, began in Japan from the 2018 to 2019 season and became the focus of attention due to its efficient viral reduction ability; therefore, we should know the prescription changes of anti-influenza agents.